Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
The Journal of Antimicrobial Chemotherapy|November 16, 2019
Variability of the HIV-1 3' polypurine tract (3'PPT) region and implication in integrase inhibitor resistanceIsabelle Malet, Olivier Delelis, Thuy Nguyen, et al.
Nucleic Acids Research|January 9, 2009
The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutationOlivier Delelis, Isabelle Malet, Li Na, et al.
Journal of Molecular Recognition : JMR|July 23, 2009
HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutationsJean-François Mouscadet, Rohit Arora, Joseph André, et al.
The Journal of Antimicrobial Chemotherapy|July 25, 2015
Combination of two pathways involved in raltegravir resistance confers dolutegravir resistanceIsabelle Malet, Eloise Thierry, Marc Wirden, et al.
The Journal of Antimicrobial Chemotherapy|September 1, 2009
Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drugMarc Wirden, Anne Simon, Luminita Schneider, et al.
AIDS (London, England)|March 3, 2006
Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitorsBénédicte Roquebert, Isabelle Malet, Marc Wirden, et al.
AIDS (London, England)|April 2, 2005
Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitutionMarc Wirden, Isabelle Malet, Anne Derache, et al.
AIDS (London, England)|October 4, 2008
Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patientsCathia Soulié, Isabelle Malet, Sidonie Lambert-Niclot, et al.
AIDS (London, England)|August 24, 2010
Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretroviralsSlim Fourati, Isabelle Malet, Mawuena Binka, et al.
The Journal of Antimicrobial Chemotherapy|February 13, 2010
Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonistsCathia Soulié, Slim Fourati, Sidonie Lambert-Niclot, et al.
Pageof 6